Metformin and Aging: A Review

Gerontology. 2019;65(6):581-590. doi: 10.1159/000502257. Epub 2019 Sep 13.


Metformin is sometimes proposed to be an "anti-aging" drug, based on preclinical experiments with lower-order organisms and numerous retrospective data on beneficial health outcomes for type 2 diabetics. Large prospective, placebo-controlled trials are planned, in pilot stage or running, to find a new use (or indication) for an aging population. As one of the metformin trials has "frailty" as its endpoint, similar to a trial with a plant-derived senolytic, the latter class of novel anti-aging drugs is briefly discussed. Concerns exist not only for vitamin B12 and B6 deficiencies, but also about whether there are adverse effects of metformin on individuals who try to remain healthy by maintaining cardiovascular fitness via exercise.

Keywords: Fisetin; Health span; Longevity; Metformin; Rejuvenation.

Publication types

  • Review

MeSH terms

  • AMP-Activated Protein Kinase Kinases
  • Aging / drug effects*
  • Animals
  • Cellular Senescence / drug effects
  • Clinical Trials as Topic
  • Electron Transport Complex I / antagonists & inhibitors
  • Humans
  • Hypoglycemic Agents / pharmacology*
  • Longevity / drug effects
  • Metformin / pharmacology*
  • Protein Kinases / drug effects
  • Rejuvenation


  • Hypoglycemic Agents
  • Metformin
  • Protein Kinases
  • AMP-Activated Protein Kinase Kinases
  • Electron Transport Complex I